Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros U.S. Tech 100 Protective Allocation Monthly Index (A100PAM)
5/31/2026, 12:00:00 AM
On May 31, 2026, Johnson & Johnson announced positive final results from the Phase 3 PROTEUS study of ERLEADA in prostate cancer; successful Phase 3 results for an oncology blockbuster typically drive a 5-10% price impact, expected.
Korean Translation
2026년 5월 31일, Johnson & Johnson은 ERLEADA의 3상 PROTEUS 연구에서 긍정적인 최종 결과를 발표함. 항암제 블록버스터의 성공적인 3상 결과는 5-10%의 주가 상승을 견인할 것으로 예상됨.
Related Recent Events
Lumentum Holdings Inc (LITE) · Earnings Release
Lumentum's next earnings release for Q4 2026 is scheduled for August 11, 2026; high importance as a primary volatility driver scheduled.
8/11/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Second Quarter 2026 financial results and conference call are scheduled for 2026-08-06 scheduled.
8/6/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Fortinet is scheduled to announce its Q2 2026 earnings results on August 5, 2026 expected. Medium importance estimated as earnings releases typically cause >5% price volatility.
8/5/2026, 12:00:00 AM
Teradyne Inc (TER) · Earnings Release
High importance is estimated as earnings reports typically drive significant volatility; Q2 2026 earnings release with revenue guidance of $1.15B-$1.25B and non-GAAP EPS of $1.86-$2.15 is scheduled.
8/4/2026, 12:00:00 AM
Axon Enterprise Inc (AXON) · Earnings Release
Market impact is estimated at Medium (>=5%) based on historical earnings volatility; Axon's Q2 2026 earnings report is scheduled.
8/3/2026, 12:00:00 AM
Amazon.com Inc (AMZN) · Earnings Release
Amazon's Q2 2026 earnings release is expected on July 30, 2026. The company guided for net sales between $194.0 billion and $199.0 billion. Low importance is assigned as the market reaction has not yet occurred expected.
7/30/2026, 12:00:00 AM